Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

U.S. Senate negotiators reach deal on $10 billion for COVID aid

Published 04/04/2022, 12:23 PM
Updated 04/05/2022, 12:35 AM
© Reuters. FILE PHOTO: U.S. President Joe Biden delivers remarks on the administration's coronavirus disease (COVID-19) surge response in the South Court Auditorium at the White House in Washington, U.S., January 13, 2022. REUTERS/Kevin Lamarque/File Photo

WASHINGTON (Reuters) -Negotiators in Congress have agreed to an additional $10 billion in COVID-19 funding to address U.S. needs but have dropped international aid from the package, Senate Majority Leader Chuck Schumer said on Monday.

The compromise, if passed, would be less than half of the $22.5 billion initially sought by U.S. President Joe Biden to combat COVID, prepare for future variants and shore up the nation's pandemic infrastructure.

White House Press Secretary Jen Psaki in a statement urged Congress to move "promptly."

"The House looks forward to considering this urgent package upon its passage in the Senate and sending it to the President's desk for signature," U.S. House of Representatives Speaker Nancy Pelosi said in a statement.

"While this agreement does not meet the Administration's full request, this package will fulfill immediate needs to secure more vaccines, boosters, testing and therapeutics to keep the pandemic at bay - and it must be enacted as quickly as possible," Pelosi added.

Biden has said more funding is needed as the world continues to fight COVID in the pandemic's third year. While U.S. officials have said they do not expect a surge from the latest BA.2 Omicron variant, they have pointed to the need to continue to make vaccines available at no cost and to boost surveillance and testing.

U.S. regulators last week approved a second booster shot for older and immunocompromised Americans, but administration officials have said without more funding from Congress money will run out for the free shots.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

"The consequences of inaction are severe," Biden warned lawmakers at a White House event last week.

Lawmakers had been weighing a $15 billion measure that included $5 billion in international aid. Health experts have said without full global immunization efforts the virus can continue to mutate, increasing the risk of infection and vaccine evasion.

Members of Congress negotiating the package, however, could not agree on how to pay for the global response.

One of the negotiators, Republican Senator Mitt Romney, said he was open to funding global efforts in a separate, "fiscally-responsible solution" in coming weeks.

A Senate vote on the $10 billion measure could come as soon as this week. Approval would send it to the House of Representatives.

Latest comments

OUT OF CONTROL, run away spending, fiat currency printing, hyper-inflation! [ NO APPROVAL ]!
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.